Panacea Biotec is a key partner in the consortium as the developer of DengiAll, a tetravalent live-attenuated dengue vaccine candidate targeting all four dengue virus serotypes and currently in late-stage development in India.
Panacea Biotec is a key partner in the consortium as the developer of DengiAll, a tetravalent live-attenuated dengue vaccine candidate targeting all four dengue virus serotypes and currently in late-stage development in India.